《半日速報》恆指半日收報26,466點 升19點; 恆生科技指數半日收報6,067點 升23點 中國宏橋跌逾5% 網易、匯控、佰澤醫療、藥捷安康-B、腦動極光-B創新高
恆指半日收26,466點,升19點或0.1%。恆生科技指數報6,067點,升23點或0.4%。國指升9點或0.1%,報9,394點。
活躍重磅股表現:
美團(03690.HK) 收99.55元,上升2.3%;
小米集團(01810.HK) 收56.7元,上升0.9%;
騰訊(00700.HK) 收646元,上升0.4%;
阿里巴巴(09988.HK) 收154.1元,下跌0.3%;
異動恆指及國指成份股:
中國宏橋(01378.HK) 收25.22元,下跌5.2%;
京東健康(06618.HK) 收66.2元,下跌4.9%;
阿里健康(00241.HK) 收6.66元,下跌4%;
申洲(02313.HK) 收61.85元,上升3.4%;
石藥(01093.HK) 收10.18元,下跌3.4%;
網易(09999.HK) 收244.6元,上升1.7%,創新高;
匯控(00005.HK) 收107.2元,上升0.7%,創新高;
異動綜合中小型股:
佰澤醫療(02609.HK) 收18.08元,上升76.6%,創新高;
藥捷安康-B(02617.HK) 收619元,上升49.2%,創新高;
腦動極光-B(06681.HK) 收13.87元,上升37.1%,創新高;
同源康醫藥-B(02410.HK) 收21.08元,上升36.1%;
MIRXES-B(02629.HK) 收72.5元,上升30.9%,創新高;
山高控股(00412.HK) 收12.08元,下跌27.4%;
博安生物(06955.HK) 收15.18元,上升16.8%;
滬上阿姨(02589.HK) 收150.9元,上升14.3%;
天立國際控股(01773.HK) 收3.25元,下跌13.6%;
健康之路(02587.HK) 收9.71元,上升13.4%;
博雷頓(01333.HK) 收52.75元,上升12.7%;
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.